Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001243191 | SCV001416331 | uncertain significance | Glycogen storage disease type III | 2022-07-30 | criteria provided, single submitter | clinical testing | This sequence change replaces histidine, which is basic and polar, with glutamine, which is neutral and polar, at codon 1309 of the AGL protein (p.His1309Gln). This variant is present in population databases (no rsID available, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with AGL-related conditions. ClinVar contains an entry for this variant (Variation ID: 968128). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Mayo Clinic Laboratories, |
RCV001507967 | SCV001713833 | uncertain significance | not provided | 2020-06-25 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001243191 | SCV002055447 | uncertain significance | Glycogen storage disease type III | 2021-07-15 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001243191 | SCV002094565 | uncertain significance | Glycogen storage disease type III | 2020-01-24 | no assertion criteria provided | clinical testing |